Skip to main content

Table 1 Characteristics of patients with MDS, MDS-AML and MDS post-treatment

From: Stem cell factor SALL4, a potential prognostic marker for myelodysplastic syndromes

  

MDS

MDS-AML

MDS post-treatment

  

RA

RCMD

RAEB-1

RAEB-2

Patients (N)

 

18

10

14

13

20

16

Gender

       
 

Male

5

6

9

7

10

10

 

Female

13

4

5

6

10

6

Age (year)

       
 

Median

36

48.5

69

65

68.5

53

 

Range

22-72

20-77

52-81

25-82

28-82

22-74

BM Blast (%)

       
 

Median

1

1.75

6.5

15.5

55

0.75

 

Range

0-3.5

0.5-4.5

5-8.5

11-19.5

23-98

0-7.5

Karyotype (N)*

       
 

Good

14

7

7

4

5

13

 

Intermediate

4

2

2

0

3

3

 

Poor

0

1

5

9

12

0

IPSS score

       
 

Median

0.5

0.5

1.25

3

––

––

 

Range

0-1

0-1.5

1-2

2-3

––

––

  1. *Karyotype: Good=normal, -Y alone, del(5q) alone, del(20q) alone; Poor=complex (≥3 abnormalities) or chromosome 7 abnormalies; Intermediate=other abnormalities.